Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1696-1700

  Lee, Won Yong ^a   Yoon, Won Tae ^a   Shin, Hee Young ^a   Jeon, Seong Hee ^a   Rhee, Poong Lyul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Helicobacter pylori; L dopa; Motor fluctuations; Parkinson's disease; Urea breath test

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; LEVODOPA;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG RESPONSE; DYSKINESIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MONOTHERAPY; MORBIDITY; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; SCORING SYSTEM; SHORT COURSE THERAPY; SINGLE DRUG DOSE; UNIFIED PARKINSON DISEASE RATING SCALE; UREA BREATH TEST;

AGED; ANTIPARKINSON AGENTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 57049147411     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22190     Document Type: Article

References (38)

1. Birkmayer W, Hornykiewicz O. Der L-3, 4-Dioxyphenylalanin (=DOPA) effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-788.
2. Cotzias CG, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
3. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
4. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
5. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
6. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992;581:261-268.
7. 3H]flunitrazepam. Neuroscience 1993;57:673-681.
8. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Arch Neurol 1992;49:1123-1130.
9. Hamlet A, Thoreson AC, Nilsson O, Svennerholm AM, Olbe L. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 1999;116:259-268.
10. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 1988;23:589-595.
11. Davies GR, Simmonds NJ, Stevens TR, et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994;35:179-185.
12. Salim AS. The relationship between Helicobacter pylori and oxygen-derived free radicals in the mechanism of duodenal ulceration. Intern Med 1993;32:359-364.
13. Kankkunen T, Huupponen I, Lahtinen K, et al. Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 2002;16:273-280.
14. Pierantozzi M, Pietroiusti A, Galante A, et al. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol 2001;50:686-687.
15. Pierantozzi M, Pietroiusti A, Sancesario G, et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci 2001;22:89-91.
16. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and 1-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-1829.
17. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
18. Fahn S, Elton RL. The unified Parkinson's disease rating scale. Florham Park, NJ: Macmillan Health Care Information; 1987.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
20. Thor P, Lorens K, Tabor S, Herman R, Konturek JW, Konturek SJ. Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia. J Physiol Pharmacol 1996;47:469-476.
21. Miyaji H, Azuma T, Ito S, et al. The effect of Helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:1303-1309.
22. 13C-urea breath test. Lancet 1987;1: 1174-1177.
23. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-1017.
24. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol 2002; 97:1113-1126.
25. 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991;32: 1461-1464.
26. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001;58:1660-1668.
27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62: 241-248.
28. Calam J. Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999;72:195-202.
29. Drake IM, Mapstone NP, Schorah CJ, et al. Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. Gut 1998;42:768-771.
30. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17-S25.
31. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47:S167-S176.
32. Shoulson I, Glaubiger GA, Chase TN. On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25: 1144-1148.
33. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
34. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478.
35. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27: 18-23.
36. Trugman JM, Hubbard CA, Bennett JP. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res 1996;725:177-183.
37. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
38. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340.